Metastatic Colorectal Cancer MedDRA version: 21.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864
Conditions
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The participant must have histologically confirmed colorectal adenocarcinoma that is metastatic and unresectable (Stage IV as defined by AJCC eighth edition) [National Comprehensive Cancer Network 2018] 2. Have measurable disease per RECIST 1.1 as assessed by the local site investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. 3. Has been previously treated for their disease and radiographically progressed on or after or could not tolerate standard treatment, which must include ALL of the following agents if approved and locally available in the country where the participant is randomized: a. Fluoropyrimidine, irinotecan and oxaliplatin. b. With or without an anti-VEGF monoclonal antibody (eg, bevacizumab) c. At least one of the anti-EGFR monoclonal antibodies (cetuximab or panitumumab) for RAS WT participants with left-sided tumors. d. Participants with BRAF v600E mutations must have been treated with a RAF inhibitor. with or without binimetinib. Participants with BRAF mutations that are not v600E are not required to have received RAF inhibitor therapy. 4. Submit an archival (= 5 years) or newly obtained tumor tissue sample that has not been previously irradiated, to enable central laboratory testing of PD-L1 and MMR status. FFPE blocks are preferred to slides. 5. Have an ECOG PS of 0 to 1 within 10 days prior to first dose of study intervention. 6. Have a life expectancy of at least 3 months, based on the investigator assessment. 7. Have the ability to swallow and retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption. 8. Have adequate organ function as defined in the study protocol. Specimens must be collected within 10 days prior to the start of study intervention. 9. Is male or female, =18 years of age at the time of obtaining the documented informed consent. 10. Male participants are eligible to participate if they agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is as follows: TAS-102 (90 days) and regorafenib (90 days). No contraception requirements are needed for males receiving MK-4280A. • Refrain from donating sperm PLUS either: • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR • Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause). Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. • Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: • Is not a WOCBP OR • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, as described in the protocol during the intervention period and for at least th
Exclusion criteria
Exclusion criteria: 1. Has previously been found to have dMMR/MSI-H tumor status determined by either IHC or PCR. 2. Has known active CNS metastases and/or carcinomatous meningitis or leptomeningeal disease. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 28 days by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid intervention for at least 14 days prior to first dose of study intervention. 3. Has a history of acute or chronic pancreatitis. 4. Has neuromuscular disorders associated with an elevated creatine kinase (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy). 5. Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability. 6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent, anti-LAG-3 antibody, with a TKI (eg, lenvatinib) other than RAF inhibitors (if appropriate), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137). 7. Has previously received regorafenib or TAS-102. 8. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PDL2 agent, anti-LAG-3 antibody, with a TKI (eg, lenvatinib) other than RAF inhibitors (binimetinib is permitted if combined with a RAF inhibitor), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137). 9. Has previously received regorafenib or TAS-102. 10. Has received prior systemic anticancer therapy including investigational agents within 28 days before randomization. 11. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease. 12. Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. 13. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days before the first dose of study intervention. 14. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 10 days prior the first dose of study medication. 15. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. 16. Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients. 17. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. 18. Has a history of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: 1. To compare MK-4280A to standard of care (regorafenib or TAS-102) with respect to overall survival.;Secondary Objective: 1. To compare MK-4280A to standard of care with respect to progression free survival per RECIST 1.1 as assessed BICR. 2. To compare MK-4280A to standard of care with respect to objective response rate per RECIST 1.1 as assessed by BICR. 3. To assess the efficacy of MK-4280A and standard of care with respect to duration of response per RECIST 1.1 by BICR. 4. To determine the safety and tolerability of MK-4280A and standard of care. 5. To compare the change from baseline in global health status/QoL, physical functioning, appetite loss and bloating for MK-4280A versus standard of care. 6. To compare the time to deterioration in global health status/QoL, physical functioning, appetite loss and bloating for MK-4280A versus standard of care. ;Primary end point(s): 1. Overall Survival (OS);Timepoint(s) of evaluation of this end point: 1. Up to approximately 26 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Progression-Free Survival (PFS) according per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) 2. Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR 3. Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR 4. Number of Participants Who Experience at least One Adverse Event (AE) 5. Number of Participants Who Discontinue Study Treatment Due to an AE 6. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score 7. Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score 8. Change from Baseline in EORTC QLQ-C30 Appetite Loss (Item 13) Score 9. Change from Baseline in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score 10. Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score 11. TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score 12. TTD in in EORTC QLQ-C30 Appetite Loss (Item 13) Score 13. TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score;Timepoint(s) of evaluation of this end point: 1. Up to approximately 19 months 2. Up to approximately 19 months 3. Up to approximately 19 months 4. Up to approximately 27 months 5. Up to approximately 24 months 6. Baseline and up to approximately 24 months 7. Baseline and up to approximately 24 months 8. Baseline and up to approximately 24 months 9. Baseline and up to approximately 24 months 10. Baseline and up to approximately 24 months 11. Baseline and up to approximately 24 months 12. Baseline and up to approximately 24 months 13. Baseline and up to approximately 24 months | — |
Countries
Australia, Canada, Chile, China, Czechia, Czech Republic, France, Germany, Israel, Italy, Japan, Korea, Republic of, Norway, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
Contacts
Public ContactGCTO
Merck Sharp & Dohme LLC
Outcome results
None listed